Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tarsons Products's total equity for the quarter that ended in Mar. 2026 was ₹6,346 Mil.
This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.
Tarsons Products Total Equity Related Terms
Tarsons Products Total Equity Historical Data
* Premium members only.
The historical data trend for Tarsons Products's Total Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tarsons Products (NSE:TARSONS) has a Total Equity of ₹6,346 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Tarsons Products and its competitors.
Is Tarsons Products' Total Equity too high?
Tarsons Products' current Total Equity is ₹6,346 Mil. Overall, Tarsons Products has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tarsons Products' Total Equity compare to ISRG and BDX?
Tarsons Products' Total Equity of ₹6,346 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Tarsons Products and its competitors. Tarsons Products's current Total Equity is ₹6,346 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsons Products stock overvalued right now?
Based on GuruFocus' analysis, Tarsons Products (NSE:TARSONS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹569.49, compared to a current price of ₹312.75 — trading 45.1% below its estimated fair value. The current Total Equity is ₹6,346 Mil. Tarsons Products' overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Tarsons Products (NSE:TARSONS), the current Total Equity is ₹6,346 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tarsons Products (NSE:TARSONS) Overvalued in 2026?
Based on GuruFocus' analysis, Tarsons Products stock appears to be undervalued.
The current stock price of ₹312.75 is trading 45.1% below its estimated GF Value™ of ₹569.49.
GuruFocus considers Tarsons Products to be Significantly Undervalued.
Key valuation signals for NSE:TARSONS:
Total Equity: ₹6,346 Mil
GF Value™: ₹569.49 vs. price of ₹312.75 (45.1% below fair value)
No single metric tells the full story. See the NSE:TARSONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tarsons Products Ltd is an Indian labware Company engaged in designing, developing, manufacturing, and marketing consumables, reusables, and other including benchtop equipment, used in various laboratories across research organizations, academia institutes, pharmaceutical companies, CROs, diagnostic companies, and hospitals. The Company is also engaged in the manufacturing of a wide range of quality labware products that help scientific discovery and improve healthcare. The company generates the majority of its revenue from the sale of manufactured plastic products. Geographically, the company generates the majority of its revenue from India.
81GF Score
Get the complete analysis for NSE:TARSONS
Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:TARSONS has been successfully added to your 
